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Abstract A targeted analytical method was established to
determine a large number of chemicals known to interfere
with the gluco- and mineralocorticoid signalling pathway.
The analytes comprise 30 glucocorticoids and 9 mineralocor-
ticoids. Ten out of these corticosteroids were primary metab-
olites. Additionally, 14 nonsteroids were included. These
analytes represent a broader range of possible adverse modes
of action than previously reported. For the simultaneous de-
termination of these structurally diverse compounds, a single-
step multimode solid-phase extraction and pre-concentration
was applied. Extracts were separated by a short linear HPLC
gradient (20 min) on a core shell RP column (2.7 μm particle
size) and compounds identified and quantified by LC-MS/
MS. The method provided excellent retention time reproduc-
ibility and detection limits in the low nanograms per litre
range. Untreated hospital wastewater, wastewater treatment
plant influent, treated effluent and river waters were analysed
to demonstrate the applicability of the method. The results
show that not all compounds were sufficiently eliminated by
the wastewater treatment, resulting in the presence of several
steroids (∼20 ng/L) and nonsteroids in the final effluent, some
of them at high concentrations up to 200 ng/L. Most of the
detected mono-hydroxylated steroidal transformation prod-
ucts were found at significantly higher concentrations than
their parent compounds. We therefore recommend to include
these potentially bioactive metabolites in environmental tox-
icity assessment.
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Introduction
For almost two decades, endocrine disrupting chemicals
(EDCs) occurring in the aquatic environment have been the
focus of environmental research, with estrogenic and andro-
genic compounds receiving most of the attention. They were
found, for example, to reduce fertility and lead to intersex and
sexual malformations in humans [1] and in wild animals [2,
3]. Yet, evidence accumulates that endocrine disruption can be
caused by other groups of compounds as well. One hypothesis
is that pharmaceuticals and other chemicals acting on the
gluco- and mineralocorticoid signalling pathway are of con-
cern due to their widespread use and potential adverse effects
on organisms in the environment [4–6].
Reports on glucocorticoid receptor (GR) agonist, found at
concentrations surpassing those of xeno-estrogens in environ-
mental waters, underline such concerns [7–9]. GR-active and
mineralocorticoid receptor (MR) active compounds, highly
used in human and animal therapeutic applications, reach the
aquatic environment because of their incomplete elimination
during wastewater treatment. Based on consumption data in
the UK, expected mean environmental concentrations of
30 ng/L and higher were calculated for the River Thames
[10] for the sum of all prescribed glucocorticoids (GCs). Of
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course, type and amount of compounds can be expected to
vary depending on country-specific drug approvals and treat-
ment of different illnesses. However, a considerable abuse of
GCs in doping (GCs are among the most frequently detected
doping agents [11]) and non-declared additives in cosmetics
also have to be expected [12]. Mineralocorticoids (MCs) are
widely used in human blood pressure control [13]. The ago-
nist potency of synthetic GCs compared to cortisol was in-
creased by introducing halogens (Cl, F) in the steroid skeleton
in order to extend their half-lives in human and animal tissues
[14]. Such modifications, however, also make them less sus-
ceptible to degradation in sewage treatment processes and in
the environment. This can explain the much lower elimination
rate [15] and higher biological GR-mediated activity [6] found
in sewage treatment plant effluents compared to estrogens.
Even so, expected environmental concentrations are in the low
nanograms per litre to micrograms per litre range, requiring
trace analytical techniques to be applied, which means an
extraction and pre-concentration step, followed by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) as
the method of choice [16].
All methods published so far only determined a small
number of GCs and only rarely MCs. For example, a study
performed in The Netherlands quantified 17 GCs and 1 MC
in wastewater [7]. In China, six GCs and one MC were
found in various waters [17, 18]; in France, ten GCs and one
MC in wastewater [19]; in Hungary, six GCs and one MC
[20] and in Spain, eight GCs and one MC in river and
wastewater [21]. None of the published studies monitored
metabolites [22, 23] or other anthropogenic chemicals po-
tentially affecting GC- or MC-hormone signalling [4]. For
example, imidazole, triazole [24] and dithiocarbamate [25]
fungicides are known to inhibit enzymes involved in corti-
costeroid bio-transformations [26], while certain substituted
PCBs [27, 28], dibutyl-tin [29] and other organotin com-
pounds [30] are GR inhibitors. However, GR-active PCBs
and organotin compounds which are well-known EDCs
could not be included in our method because, based on
either their physicochemical properties or their very low
environmental concentrations, they require a completely dif-
ferent analytical procedure. Hence, the goal of the work
presented here was to develop a robust method for the
analysis of all frequently applied GR- and MR-binding
pharmaceuticals, including several transformation products
as well as chemicals interfering with steroid genesis. Thus,
up to 30 GCs and 9 MCs, including 10 primary corticoste-
roid metabolites, and 14 nonsteroidal compounds (see
Table 1) were selected. We show that the method is appli-
cable to different matrices such as untreated wastewater,
treated wastewater and river water. To our knowledge, this
method allows monitoring the most complete selection of
compounds expected to interfere with the GC- and MC-
hormone signalling pathways.
Experimental part
Chemicals and solutions
Standard compounds (STD) were obtained from Sigma-
Aldrich and deuterated internal standards (IS) from CDN
isotopes (Dr. Ehrenstorfer, Augsburg; see Table 1). They were
used without further purification to prepare standard solutions
in ethanol stored at −20 °C. The structures of the steroidal
compounds are given in Table 2. Organic solvents were of
HPLC gradient-grade purity from Acros or Scharlau.
Sample collection
Wastewater from a hospital (Kantonsspital Aarau, Baden,
Switzerland), a wastewater treatment plant (WWTP, Baden)
and water from two rivers were sampled. Hospital wastewater
outflow and WWTP influent and effluent were collected time
proportionally: hospital wastewater during 3 h (250 mL every
10 min) and the others by a built-in WWTP auto-sampling
device during 6–8 h. River water (Limmat) was obtained from
four grab samples upstream (1.4 km) and downstream
(1.6 km) of the WWTP, and from a second river (Thur at
Frauenfeld) running through agricultural land but 5.0 km
downstream of a small WWTP. Samples were cooled during
transport to the lab. Purified water (18 MΩ) handled like a
sample provided the solutions for method blank values.
Sample preparation and solid-phase extraction
Samples were spiked with five deuterated IS (Table 1, 100 ng/
L each). River water (1 L), wastewater effluent (1 L), and
untreated wastewater (0.5 L) were filtered through glass fibre
(GF/F (0.7 μm), Whatmann) the same day of sampling and
stored at 4 °C in the dark. Ammonium formate was added to
the samples to reach 15 mM and pH 6.50–6.85, and solid-
phase extraction (SPE) was performed on a SPE cartridge
consisting of Env+ (150 mg, Separtis), Strata-X-CW
(100 mg, Phenomenex) , Stra ta-X-AW (100 mg,
Phenomenex) and Oasis HLB (200 mg, Waters). This solid-
phase mixture has been developed in-house and successfully
applied to extract a wide range of chemicals from the water
[31].
Adsorbed compounds were eluted twice with 5 mL acidic
(2 % formic acid) methanol/ethyl acetate (1:1). The pooled
solvents were evaporated under a gentle N2 stream. The
residue was transferred to a conical vial (1.5 mL size), and
the solvent was again evaporated down to ∼10–20 μL which
then was air-dried.
Injection solutions were prepared by dissolving the residue
in 30 μL methanol followed by the addition of 70 μL aceto-
nitrile. This solutionwas diluted 1:10 or 1:5 in a 1:1 mixture of
HPLC eluents A and B.
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Table 1 List of analysed corticosteroids and nonsteroidal compounds expected to interfere with the gluco- and mineralocorticoid hormone signalling
pathway
Name Abbreviation CAS Formula Status log Kow
Glucocorticoidsa
Betamethasone BMS 378-44-9 C22H29FO5 STD 2.0
Betamethasone D5 BMS D5 – C22H24D5FO5 IS 2.0
Budesonide BDN 51333-22-3 C25H34O6 STD 3.2
Clobetasol CBS 25122-41-2 C22H28ClFO4 STD 2.5
Clobetasol propionate CBP 25122-46-7 C25H32ClFO5 STD 3.5
Clobetasol propionate, HO- CBP OH – C25H32ClFO6 –
Corticosterone CRC 50-22-6 C21H30O4 STD 1.9
Cortisone CRT 53-06-5 C21H28O5 STD 1.5
Cyproterone acetate CYP 427-51-0 C24H29ClO4 –
Desonide DSN 638-94-8 C24H32O6 –
Dexamethasone DMS 50-02-2 C22H29FO5 STD 1.8
Dexamethasone-21-acetate DMS 21-ac 1177-87-3 C24H31FO6 STD 2.9
DMS, HO-/BMS, HO- – C22H29FO6 –
Flumetasone FMS 2135-17-3 C22H28F2O5 STD 1.9
Fluorometholone FMT 426-13-1 C22H29FO4 STD 2.0
Fluticasone propionate FTS prop 80474-14-2 C25H31F3O5S STD 3.7
Halometasone HMS 50629-82-8 C22H27ClF2O5 2.9
Hydrocortisone (cortisol) HCRT 50-23-7 C21H30O5 STD 1.7
Hydroxycortisol HCRL 3078-34-0 C21H30O6 –
Medroxyprogesterone MPG 520-85-4 C22H32O3 STD –
Megestrol MGS 3562-63-8 C22H30O3 –
Megestrol acetate MGS ac 595-33-5 C24H32O4 –
Methylprednisolone, 6α- MPNL 83-43-2 C22H30O5 STD 2.4
Mifepristone MFP 84371-65-3 C29H35NO2 STD –
Prednisolone PNL 50-24-8 C21H28O5 STD 16
Prednisone PNS 53-03-2 C21H26O5 STD 1.4
Prednisone, HO- PNS OH – C21H26O6 –
Triamcinolone acetonide TRM acetone 76-25-5 C24H31FO6 STD 2.3
Triamcinolone acetonide TRM OH acetone – C24H31FO7 –
Mineralocorticoidsa
Aldosterone ALD 52-39-1 C21H28O5 STD 1.1
Eplerenone EPR 107724-20-9 C24H30O6 STD 2.4
Eplerenone, 6β-HO EPR 6-OH – C24H30O7 –
Eplerenone, 21β-HO EPR 21-OH – C24H30O7 –
Fludrocortisone 21acetate FDCac 514-36-3 C23H31FO6 STD 1.7
Hydroxyprogesterone, 21- PGS 21-OH 64-85-7 C21H30O3 STD 2.9
Progesterone PGS 57-83-0 C21H30O2 STD 3.8
Progesterone D9 PGS D9 15775-74-3 C21H21D9O2 IS –
Spironolactone SRL 52-01-7 C24H32O4S STD 2.8
Spironolactone, HO- SRL-OH C24H32O5S –
Nonsteroids
Bicalutamide BCT 90357-06-5 C18H14F4N2O4S STD 3.4
Cimetidine CMD 51481-61-9 C10H16N6S STD 0.5
Clotrimazole CLT 23593-75-1 C22H17C1N2 STD 4.9
Daidzein DIZ 486-66-8 C15H10O4 STD 2.9
Daidzein D4 DIZ D4 1219803-57-2 C15H6D4O4 IS 2.9
Fluconazole FCZ 86386-73-4 C13H12F2N6O STD 0.5
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Chromatography
An Agilent 1100 HPLC, with the mixer column replaced by a
frit, was used with in-line degasser, auto-sampler and column
oven (45 °C) to run samples on a Poroshell 120 EC18 column
(2.1×100 mm, 2.7 μm, Agilent) protected by a C18 guard
column (EC18, 2×4 mm). A linear gradient (300 μL/min) was
applied starting from 0 min with 85 % A (90 % H2O, 10 %
acetonitrile, 10 mM NH4HCOO pH 5.8) and 15 % B (10 %
H2O, 90 % acetonitrile, 10 mMNH4HCOO pH 6.2) to 100 %
B in 21 min and back to initial condition within 1 min follow-
ed by equilibration for 4 min. Deuterated IS compounds (see
Table 1) were selected as retention time (tR) markers, spanning
the whole chromatogram.
Mass spectrometry
The column was coupled to the Turbo Spray ESI inlet of an
API4000 triple quad MS (AB Sciex). The collision energy
(CE) for the collision induced dissociation was optimised for
each standard compound and transition. ESI+ conditions were
the following: needle voltage, 4500 V; declustering potential,
20; entrance potential, 10; collision cell exit potential, 15 and
interface temperature, 450 °C. For each target compound, two
transitions were monitored in a single reaction monitoring
(SRM) mode at FWHM=0.7 resolution during the whole
chromatogram (see Tables 2 and 3). Measuring all transitions
in one run gave a too long duty cycle; therefore, the samples
were run twice, each with a different set of transitions (duty
cycle, 1.3 and 1.6 s, resp.), in order to get a full chromato-
graphic track of each transition and to measure a sufficient
number of data points across a chromatographic peak. Both
transitions of a compound, if equally favourable, were used
for quantification; otherwise, only the one with the better S/N
ratio was applied. Peak areas were calculated by Analyst 1.5
software and manually adjusted before transferring to Excel,
together with the retention times, for further processing.
Data processing and evaluation
Blank values for the whole workup, pre-concentration and
measurement procedure were obtained by deuterated standard
addition to purified water (1 L), which was handled as a
sample. Blank values were calculated as integrals over the
expected peak base width and subtracted from samples before
quantitation. Background equivalent concentrations (BEC)
were calculated from blank samples and subtracted from other
samples. Recoveries over the whole workup and pre-
concentration were obtained from five deuterated chemicals
(Table 1) spiked into a blank sample. Concentrations given in
Table 4 are corrected by the recovery of the nearby eluting
deuterated IS. Mono-hydroxylated metabolite concentrations
were calculated from parent compound calibrations. Detection
limits depend on the matrix, which was different in each
sample; therefore, BEC are used to calculate detection limits
(DL; Table 4) as an approximation of variable DL in real
samples.
Results and discussions
Target compound selection
Target compounds (see Table 1, also for abbreviations) were
selected according to their role in the GC- and MC-hormone
signalling pathways. GR and MR agonists and antagonists
used in rather frequent medical applications were extracted
Table 1 (continued)
Name Abbreviation CAS Formula Status log Kow
Fluconazole D4 FCZ D4 1124197-58-5 C13H8D4F2N6O IS –
Genistein GNS 446-72-0 C15H10O5 STD 3.0
Glycyrrhetinic acid GYR 471-53-4 C30H46O4 IS 2.7
Ketoconazole KTZ 65277-42-1 C26H28C12N4O4 STD 3.4
Ketoconazole D8 KTZ D8 C26H20D8C12N4O4 STD 3.4
Metyrapone MYP 54-36-4 C14H14N2O STD 1.4
Miconazole MCZ 22916-47-8 C18H14C14N2O STD 5.3
β-Naphthoflavone NTF 6051-87-2 C19H12O2 STD 4.9
Pravastatin PRV 81093-37-0 C23H36O7 STD 1.3
Quercetin QRC 117-39-5 C15H10O7 STD 1.8
Resveratrol RVR 501-36-0 C14H12O3 STD 2.6
Status: STD: a reference compound was applied as a standard
IS internal standard
a Classifies steroids according to a potential effect on the signalling path
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from the list of approved drugs issued by the Swiss drug
approval administration (Swissmedics) [32]. These drugs are
present in many human and veterinary medications. A cross
reactivity between theMR and GR [33] makes it mandatory to
include MCs. Quantifying both MR and GR-active com-
pounds is therefore particularly important. For rather frequent-
ly prescribed steroids, like BMS, CBP, DMS, EPR, PGS, SRL
and TRM (see Table 1), the mono-hydroxylated metabolites
were included in the target list since these primary metabolites
are often hydroxylated [34] at a position which only partly
reduces their pharmaceutical activity (e.g. EPR [35], BDN
[23]). The ratio of the original drug to its metabolites in
receiving waters is largely unknown and likely variable. For
instance, chemicals from topical applications and direct dis-
posals will only be transformed in the WWTP, while ingested
drugs will be metabolised in the living body before entering
Table 2 Structural features and experimental details of analysed steroids. MS-detection settings for SRM (Q1: precursor mass, Q3: fragment mass, CE:
collision energy) and observed retention times (tR)
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the WWTP via excretion. Another reason to include metabo-
lites is the fact that some drugs are sold as inactive forms (e.g.
cortisone, prednisone), so-called prodrugs, which are easily
transformed to active compounds (hydrocortisone (cortisol),
prednisolone). Other prodrugs contain readily hydrolysable
side chains that facilitate the uptake (e.g. acetate, propionate;
see Table 2).
Odermatt et al. [36, 4] reported on a large number of
nonsteroidal environmental chemicals that could potentially
affect GC- and MC-hormone signalling pathways. Based on
these considerations, specific enzyme inhibitors of the steroid
biosynthesis and biotransformation have been included in the
target list for the current work because an impairment of these
enzymes also contributes to the overall disruption of pathways
of interest [36]. The analysed nonsteroids (listed in Table 1)
represent a large variety of chemicals acting as phytohor-
mones and enzyme inhibitors (fungicides, lipid lowering
drugs) or being used as dietary supplements and flavours.
Solid-phase extraction
The targets included in this study are compounds of diverse
polarities spanning 5 orders of magnitude in logKow (Table 1).
Theywere successfully extracted and enriched by a mixture of
commercially available extraction phases in a single-step mul-
timode SPE cartridge [37], circumventing multiple laborious
single extraction steps each geared to a specific substance
class.
Some eluted cartridges have further been extracted by
solvents of decreasing polarity similarly to the fractionation
procedure reported for steroid metabolomics in tissues [38].
Acidified methanol/ethyl acetate recovered acidic polar to
medium-polar compounds in the first fraction. Thereafter,
basic ethyl acetate methanol (1:1, 2 % ammonia) was applied
to elute strongly basic, if any, polar compounds. A third
faction was obtained by eluting with ethyl acetate alone and
a fourth by cyclohexane which could remobilize increasingly
lipophilic compounds from the cartridges. Fractionating elu-
tion reduces the matrix content in a fraction and thus leads to
less ion suppression and interferences during detection.
However, the analysis of these fractions showed that all stan-
dard compounds eluted in the first fraction (50–100 %) and
that only the basic compounds, miconazole and ketoconazole,
were found in fraction 2 (up to 50 %). Other concentrations
found in fraction 2 of a hospital wastewater sample were low
(generally ten times lower than in fraction 1). These findings
justify our decision to analyse exclusively fraction 1 by LC-
MS/MS. Possible losses are accounted for by the deuterated
IS. Pre-concentration factors of 1000 for less matrix contain-
ing samples (river water, WWTP effluent) and 500 for sam-
ples with higher matrix content (nontreated wastewater) were
used.
Recoveries from the blank solutions (30–80 %, calculation
based on the IS) were comparable or slightly lower than those
found in the samples (36–100 %), possibly due to the higher
ionic strength in the samples which forces analytes into the
organic phase. The mixed-mode phase is optimal for co-
extracting different compound classes but gave a broad recov-
ery range similar to the one reported (25–82 %) for ten GCs
eluted from Oasis HLB phase using AcOEt and from Isolute
ENV+ using methanol [21]. While methanol is required to
elute the more polar nonsteroids, it is a less suitable solvent for
corticosteroids. This might explain the broad recovery range.
Table 3 Experimental details (for abbreviations see Table 2) of analysed
nonsteroidal compounds expected to interfere with the cortico hormone
signalling pathway
Nonsteroids tR Q1 Q3 CE
Min m/z m/z V
Bicalutamide 10.2 431 217 20
431 187 20
Cimetidine 0.6 253 117 18
253 159 18
Clotrimazolea 13.5 277 165 30
277 241 30
Daidzein 4.1 255 137 37
255 199 37
Daidzein D4 4.2 259 231 37
259 203 37
Fluconazole 1.8 307 220 30
307 238 30
Fluconazole D4 1.7 311 243 25
311 224 25
Genistein 6.0 271 153 40
271 215 40
Glycyrrhetinic acid 14.3 471 177 45
471 135 50
Ketoconazole 10.8 531 489 45
244 45 531
Ketoconazole D8 10.9 539 497 45
539 185 45
Metyrapone 4.0 227 121 25
227 106 25
Miconazole 16.1 417 159 35
417 161 35
β-Naphthoflavone 14.1 273 171 38
273 129 38
Pravastatina 12.7 469 263 32
469 187 32
Quercetin 12.5 303 153 35
303 137 35
Resveratrol 10.6 229 136 20
229 195 2
aNo [M+H]+was observed
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Table 4 Concentrations (ng/L) found in Swiss rivers and wastewaters. Values from three river waters are given as a range. Detection limits apply for
river waters
Name DL Waste waters River waters
Hospital WWTP inflow WWTP effluent
Glucocorticoids
Betamethasone+dexamethasone <2 1720 106 15 8–13
BMS, DMS, 21acetate <1 4 <2 4 <1–13
BMS, −HO+DMS, −HO (<1) (40) (34) (19) (10–14)
Budesonide <0.5 4 1 <1 1–4
Clobetasol <0.5 1 4 <1 <0.5–1
Clobetasol propionate <0.5 7 7 <1 <1
Clobetasol propionate HO (<0.5) (10) (5) (<1) (<1–3)
Corticosterone <1 14 21 5 4–6
Cyproterone acetate (<0.5) (27) (<1) (<1) (<1)
Desonide (<0.5) (<1) (<1) (<1) (<1)
Flumetasone <1 5 6 3 1–2
Fluorometholone <0.5 2 3 <1 <0.5–1
Fluticasone propionate <0.5 5 4 <1 <1
Halometasone (<0.5) (8) (<1) (1) (1–5)
Hydrocortisone+cortisone <5 378 160 26 7–10
Hydroxycortisol, 6β- (<5) (<10) (<10) (<10) (<4)
Medroxyprogesterone <1 42 6 <2 1–5
Megestrol (<0.5) (17) (69) (<1) (1–2)
Megestrol acetate (<0.5) (11) (<1) (<1) (<1)
Methylprednisolone, 6α- <0.5 36 8 1 3–5
Mifepristone <1 17 <2 <1 <1
Prednisolone+prednisone <4 1221 336 <5 10–12
Prednisolone+prednisone (<4) (616) (843) (18) (4–45)
Triamcinolone acetonide <1 14 6 1 <1
Triamcinolone acetonide HO (<1) (54) (2) (<1) (<1)
Mineralocorticoids
Aldosterone <1 22 19 2 <1–2
Eplerenone <1 11 6 4 2–3
Eplerenone, 21-HO (<0.5) (25) (34) (<1) (1–2)
Eplerenone, 6β-HO (<0.5) (9) (4) (2) (1–3)
Fludrocortisone acetate <1 82 36 12 5–14
Hydroxyprogesterone, 21- <1 11 5 <2 1–3
Progesterone <1 15 4 <1 4–10
Spironolactone <1 130 36 2 1–4
Spironolactone OH (<1) (217) (315) (<2) (<1–2)
Nonsteroids
Cimetidine <0.5 5 5 2 <0.5–2
Clotrimazole <2 17 27 23 31–47
Daidzein <2 671 1538 <3 <2
Fluconazole <2 4640 236 200 4–18
Fluconazole <1 456 2049 28 5–8
Glycyrrhetinic acid <8 2829 85 13 <8–23
Ketoconazole <0.5 4 142 15 <1
Metyrapone <5 <10 <10 <5 <5
Miconazole <0.5 2 15 <1 <1
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Fluconazole, eluting 1min after the void volume, was the only
deuterated IS showing higher than 100 % recoveries in waste-
water. Similar recoveries from pure water and from samples
confirm that ion suppression in the ESI source and/or contri-
bution from interfering masses must either be balanced or are
basically absent, except for compounds fromwastewater sam-
ples eluting near the front. These samples always contain a
larger number of in front eluting compounds causing interfer-
ences compared to less matrix-loaded samples.
Chromatography
Usually, for highest separation efficiency, UPLC is applied
with column-packing material of less than 2 μm diameter and
backpressures above 400 bar. Since these conditions exceed
the pressure limit of our pump, we used a core shell column
material (2.7 μm) which provides a separation similar to
UPLC but, in combination with the low viscosity of acetoni-
trile at 45 °C, considerably less backpressure (<250 bar). A
linear gradient starting at 18 % acetonitrile and running up to
90 % within 20 min sufficiently separated all the compounds
in 18 min. Herrero et al. recently reported a shorter run time
(13 min) for nine GCs only [21] on a 50×4.6 mm column and
1 mL/min at 50°. In another publication, acetonitrile was
reported to be the best solvent for an efficient separation and
lower backpressure, while 2-propanol provided higher re-
sponse for cortisol in ESI MS [39]. In our setup, however, 2-
propanol produced too high a backpressure and a suboptimal
separation, which is why, despite the higher sensitivity, we
refrained from using it. The applied acetonitrile gradient pro-
vided stable retention times (e.g. triamcinolone acetonide at
tR=7.40 min, STDEV=0.02 min, n=78), an important crite-
rion for compound identification. The separation of STD
compounds is shown in Fig. 1 and retention times are given
in Tables 2 and 3. Retention time windows were determined
experimentally for standards. For compounds where no stan-
dard was available, retention time windows were estimated
based on the experimentally determined tR of the most similar
STD compound or in analogy to published data. For the tR
assignment of mono-hydroxylated corticosteroid transforma-
tion products, a tR difference between parent and product
compound similar to that published for EPR and EPR-OH
[35] was assumed. Retention times of matrix-free STD mix-
tures and environmental samples did not show any shift due to
the matrix. All in all, the short mass transfer on the core shell
particles provided a high separation efficiency.
Mass spectrometry
In order to find the most sensitive transition for each STD
compound, their fragmentation behaviour was investigated
using different collision energies at varying acetonitrile con-
tent (20–80 %). The generated main fragments agreed well
with literature data. Some changes in relative intensities were
observed for lowest acetonitrile contents which did not dras-
tically reduce sensitivity. ESI detection of corticoids in posi-
tive ion mode ([M+H]+) has been reported to provide a higher
response than in the negative ion mode [38, 7]. This was
confirmed by our own experiments. Both formic acid and
ammonium formate were evaluated as proton donors in
ESI+, but almost no difference could be observed. The am-
monium formate salt with the pH adjusted to close to neutral
was preferred since some of the compounds are not stable
under strongly acidic conditions in combination with an ele-
vated column temperature. Two precursor-fragment ion tran-
sitions were monitored for each compound. For SRL, CLTand
PRV, no [M+H]+ was observable. SRL and SRL-OH readily
lost thioacetic acid, so that only the resulting M-CH3COSH
ion (m/z 341 and 357) was available as precursor ion instead.
The imidazole ring was cleaved off from CLT, yielding the
mono-chlorinated triphenylmethane fragment (m/z 277) as
precursor, while PRV was detected as its formate adduct only.
Method performance
The method was developed using 38 standard compounds and
5 deuterated IS compounds (see Table 1) selected to cover the
whole chromatographic run time. Their measured properties
(tR, fragmentation pattern) and literature data served as the
basis for deducing retention times and transitions for targets
not purchased as STD compounds (see Table 1). Among the
initial non-STD targets, dexamethasone-21-acetate,
Table 4 (continued)
Name DL Waste waters River waters
Hospital WWTP inflow WWTP effluent
β-Naphthoflavone <0.5 1 <1 <1 <0.5–1
Pravastatin <5 69 39 <5 <5–8
Quercetin <100 <200 <200 <100 <100
Resveratrol <150 <300 <300 <150 <150
Values in brackets were calculated from a calibration with a STD compound of similar but not identical structure (see text)
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budesonide and 6α-methylprednisolone were detected at sig-
nificant concentrations in environmental samples and for this
reason were purchased too for reliable quantification.
Bicalutamid was not stable in diluted STD compound mix-
tures and was therefore not quantified.
For surface waters, BEC multiplied by 5 were used to
represent DL which are in the few nanograms per litre range
for all of the compounds (Table 4), except for the less stable
flavones, quercetin and resveratrol. For samples with a higher
matrix load, BEC multiplied by 10 approximates DL more
realistically. Stable tR allowed to accept peaks only within a
narrow (±0.1 min) tR window, and monitoring two collision
energy optimised transitions per target analyte provided a
reliable compound identification. The concentrations deter-
mined (see Table 4) are adequately validated by referencing
to appropriate deuterated IS and the use of structurally iden-
tical calibration standards for quantification.
The similarity of the steroidal structures (see Table 2),
producing similar or identical fragments, is prone to cross
contributions from insufficiently separated analytes. The crit-
ical cases encountered are listed in Table 5. Aldosterone,
cortisone and prednisolone have the same isobaric protonated
molecule ions (m/z 361.3). ALD has a significantly different
retention time and hence cannot contribute to the CRT and
PNL fragments and vice versa. CRT and PNL are co-eluting;
however, CRT does not produce fragment m/z 147 at CE 20
used to quantify PNL, and PNL does not produce fragmentm/
z 163 at CE 30 which is used to quantify CRT. Hence, all three
compounds can be quantified without cross contribution.
Other cross sensitivities have been investigated under increas-
ing concentrations (10–20-fold) of the possible contributor but
were negligible in most cases. For instance, PNS contributed
1.7 % (per μg/mL) to PNL, whereas EPR contributed 1.2 % to
D5-betamethasone due to the overlapping isotope pattern.
However, closely eluting and the same fragment forming pairs
like HCRT/CRT and PNL/PNS showed a much higher cross
contribution. The intensity of the CRT transition 361→163
was composed of up to 40 % by the HCRT transition 363→
163, and PNL contributed 6.0 % to PNS, which is not possible
PNS
EPR
BMS
DMS
FMS CRC
CRT
TRM
PGS-OH
BCT
SRL
KTZ
DMSac
PGS
MFP
FTS
CLT
FCZ
ALD
PNL
CRT
HCRT
Fig. 1 Overlaid chromatograms detecting 22 compounds by 66 SRMs in a mixture of 34 STD compounds. Chromatograms were background subtracted
but not smoothed
Table 5 Sets of com-
pounds with similar or
identical [M+H]+ m/z
values and retention
times
Compound Q1 Q3 tR
Prednisone 359 341 5.0
Prednisone 359 323 5.0
Aldosterone 361 343 4.2
Aldosterone 361 315 4.2
Prednisolone 361 343 5.
Prednisolone 361 147 5.1
Cortisone 361 163 5.1
Cortisone 361 121 5.1
Hydrocortisone 363 121 5.3
Hydrocortisone 363 327 5.3
Betamethasone 393 147 6.7
Betamethasone 393 355 6.7
Dexamethasone 393 147 6.8
Dexamethasone 393 279 6.8
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by an overlapping isotope pattern but, in this case, must be due
to an ESI insource reduction of the alcohol to the ketone. Such
pairs require a ratio around 1:1 or a better separation between
the two to be quantified separately.
Therefore, closely eluting compounds producing the same
fragments (e.g. BMS and DMS [40]) cannot be assigned unam-
biguously if in a sample only one single peak appears close to
the expected tR. Even small tR variations can make the assign-
ment uncertain. The peaks can be allocated correctly only when
both compounds are present approximately in the same concen-
trations. As this is not the case in all samples, the peak integra-
tion window was selected wide enough to integrate both com-
pounds. Accordingly, the following pairs are quantified as the
sum of two compounds: PNS/PNL, CRT/HCRT and BMS/
DMS and accordingly BMS 21-ac/DMS 21-ac (see Table 4).
For 16 compounds, finally, we did not work with identical
standard compounds (see Table 1) because they were not avail-
able or too expensive in relation to their relevance. The concen-
trations of these compounds were calculated from a calibration
of a standard with similar structure and therefore cannot be
considered as accurate concentrations (indicated by brackets in
Table 4). These values are useful as indicators of low or high
possible concentrations but can be correctly determined only by
using the corresponding standard compounds.
Mono-hydroxylated metabolites showed in most cases sig-
nificantly higher concentrations than their parent compounds.
Although no reference metabolites were available, it can rea-
sonably be assumed that their chemical behaviour and hence
MS response is similar to their parent compound. Also the
correct identification of the mono-hydroxylated metabolites is
highly probable since, beside the two monitored transitions,
the expected tR difference to their precursor corresponds ex-
actly to the one found for EPR and EPR-OH, both were
structurally identified [35].
Application
The method presented was applied in a first-trial cam-
paign to analyse wastewaters and their corresponding
receiving river waters [41]. Concentrations found in
river waters are summarised in Table 4, and typical
chromatograms are shown in Fig. 2. Lowest analyte
concentrations, mostly around or below detection limits,
were found in river waters, and samples from different
locations did not show relevant concentration differ-
ences. This is likely due to a large dilution and good
mixing of WWTP eff luents wi th r iver water.
Nevertheless, several GCs/MCs reach concentrations
around 10 ng/L in river waters and the two nonsteroids
enzyme inhibitors fluconazole and clotrimazole reach
even higher concentrations. The two are used as fungi-
cides in many approved over-the-counter drug prepara-
tions (53 in Switzerland [32]), including non-GC and
non-MC medications. All the compounds measured here
in river water samples add up to around 200 ng/L,
which are clearly in the range (100–1000 ng/L), pro-
ducing increased glucose levels and decreased
leucocytes in fathead minnows [9].
The concentration differences between treated WWTP ef-
fluent (see Table 4 and Fig. 3) and nontreated WWTP inflow
DIZ D4
DIZ
FCZ
CLT
BMS D5
BMS
DMS
BCT
KTZ
Fig. 2 Overlaid chromatograms of identified compounds in a river water sample. Chromatograms were not background subtracted and not smoothed
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are also evident. However, eight compounds are eliminated
only by 50–80 % during the treatment which parallels the
findings of an insufficient decrease of biological glucocorti-
coid activities in an EDC study on Swiss wastewater treatment
plants [15]. As expected, high concentrations were observed
in untreated wastewater (see Table 4 and Fig. 3b), the highest
in hospital wastewater with lowest dilution and no
elimination. Steroid metabolization already occurred to a large
extent since mono-hydroxylated derivatives are present at
high concentrations and the ratio to their precursor further
increases until the compounds reach the WWTP. However, a
single combined sample over 4 h might not be representative
for the general use of pharmaceutical in this hospital over a
longer time [42].
A
B
DIZ
FCZ
CLT
BMS D5
BMS
DMS
x
x
ALD
x
CLTx
FCZ
Fig. 3 Overlaid chromatograms of identified compounds in wastewater, a WWTP inflow sample (a) and a treated wastewater sample (b, WWTP
effluent). Chromatograms were background subtracted but not smoothed and peaks denoted by x are not due to target compound
LC MS/MS of cortico endocrine diruptors 7663
Conclusions
The results show that the developed method is well suited to
analyse a large number of diverse chemicals acting on the
corticoid signalling pathway, be that by direct interaction with
nuclear receptors or steroid genesis. The high separation effi-
ciency and sensitivity of the developed LC-MSmethod allows
determining these compounds with the high sensitivity (ng/L)
required for the low concentrations typically found in diverse
environmental matrices. The work presented also shows that
primary corticosteroid metabolites not monitored thus far and
some nonsteroids are indeed released together into the envi-
ronment. The concentration level they reach together with
several GCs and MCs suggests a disruption of the GC- and
MC-hormone signalling pathways in aquatic organisms is
most likely. Furthermore, halogenated corticosteroids and
their esters are likely to be the main contributors to the
corticoid-like activities found in environmental waters due to
their higher stability, higher potency and lower elimination
rate. For assessing the environmental risks, the biological
activity of all the compounds found has to be known. More
work is needed to reveal effects of a mixture of corticoids, its
primary metabolites and higher concentrated fungicides in
disturbing the corticosteroid signalling pathway. Single chem-
ical compound analysis, as described here, needs to be com-
bined with an assay for biological effects.
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